Evaluation of Myocardial Contractility Determination with Tissue Tracking Echocardiography after Levosimendan Infusion in Patients with Poor Left Ventricular Function and Hemodynamics
Background: The aim of this study was to assess the effect of conventional inotropic drugs compared to levosimendan using tissue tracking echocardiography in the early postoperative period for patients with low ejection fraction undergoing coronary artery bypass graft (CABG) surgery.
Methods: We prospectively analyzed 115 patients (69 male, 46 female) who planned for elective coronary artery bypass surgery with low ejection fraction, ?% 30, from September 2012 to December 2013. Patients were divided into two groups. Levosimendan was used at a loading dose of 15 ?g/kg/min for the first twenty minutes, and continued at a maintenance dose of 0.2 ?g/kg/min six hours before the anesthetic induction in group I (n = 47, 23 male, mean age 67.16 ± 4.72 years). Dopamine at 10 ?g/kg/min and/or dobutamine at 10 ?g/kg/min were used at the time of weaning from cardiopulmonary bypass in group II (n = 68, 47 male, mean age 65.43 ± 6.12 years). The patients were evaluated preoperatively and on the fifth postoperative day by transthoracic echocardiography. Patients were also evaluated just before the cardiopulmonary bypass and at the 12th and 24th hours on the first postoperative day by transesophageal echocardiography. Student t test and ?2 test were used for statistical analyses.
Results: There were no significant differences in demographics and preoperative hemodynamic parameters between groups I and II. Hemodynamic and echocardiographic parameters were significantly better in group I receiving levosimendan, compared to group II.
Conclusion: Levosimendan enhances functional myocardial tissue mass and ensures positive hemodynamic effect in the early postoperative period in patients with low ejection fraction undergoing elective CABG.
Aksun M, Karahan N, Adanir T, et al. 2009. Timing of levosimendan in cardiac surgery. Anatolian J Cardiol 9:223-30.nAlvarez J, Bouzada M, Fernandez AL, et al. 2006. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol 59:338-45.nBorges AC, Kivelitz D, Walde T, et al. 2003. Apical tissue tracking echocardiography for characterization of regional left ventricular function: comparison with magnetic resonance imaging in patients after myocardial infarction. J Am Soc Echocardiogr 16:254-62.nD'hooge J, Heimdal A, Jamal F, et al. 2000. Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur J Echocardiogr 1:154-70.nDe Hert SG, Lorsomradee S, Cromheecke S, et al. 2007. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anest Analg 104:766-73.nDe Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. 2006. Evidence-based use of levosimendan in different clinical settings. Review. Eur Heart J 27:1908-20.nFabiato A, Fabiato F. 1979. Calcium and cardiac excitation-contraction coupling. Ann Rev Physiol 41:473.nFiggitt DP, Gillies PS, Goa KL. 2001. Levosimendan. Drugs 61:613-27.nFollath F, Cleland JG, Just H, et al. 2002. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196.nGoebel B, Arnold R, Koletzki E, et al. 2007. Exercise tissue Doppler echocardiography with strain rate imaging in healthy young individuals: feasibility, normal values and reproducibility. Int J Cardiovasc Imaging 23:149-55.nGray R, Shah PK, Singh B, Conklin C, Matloff JM. 1981. Low cardiac output states after open heart surgery. Comparative hemodynamic effects of dobutamine, dopamine, and norepinephrine plus phentolamine. Chest 80:16-18.nLabriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B. 2004. Hemodynamic effects of levosimendan in patients with low output heart failure after cardiac surgery. Int J Clin Pharm Th 42:204-6.nLehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. 2004. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 10:89.nLiileberg J, Nieminen MS, Akkila J, et al. 1998. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary bypass grafting. Eur Heart J 19:660-3.nÖnem G, Saçar M, Aybek H, et al. 2012. Protective effects of cilostazol and levosimendan on lung injury induced by lower limb ischemia-reperfusion. Turkish J Thorac Cardiovasc Surg 20:577-83.nÖner S, Kür?at BA, Asuman S, Zuhal A, Ayd?n B. 1996. The comparison of the inotropic effects of levosimendan and amrinone after ischemia in isolated perfused guinea pig hearts. Turkish J Thorac Cardiovasc Surg 4:5-8.nPan C, Hoffmann R, Kühl H, Severin E, Franke A, Hanrath P. 2001. Tissue tracking allows rapid and accurate visual evaluation of left ventricular function. Eur J Echocardiogr 2:197-202.nRomson JL, Leung JM, Bellows WH. 1999. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology 91:1318-21.nSalomon NW, Plachetka JR, Copeland JG. 1981. Comparison of dopamine and dobutamine following coronary artery bypass grafting. Ann Thorac Surg 3:48-51.nSogaard P, Egeblad H, Pedersen AK, et al. 2002. Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. Circulation 106:2078-84.nVoigt JU, Flachskampf FA. 2004. Strain and strain rate. New and clinically relevant echo parameters of regional myocardial function. Z Kardiol 93:249-58.nYa?ar S, Yava? S, Kervan Ü, Balc? M, Özgök A. 2012. The effect of high-dose GIK infusion on cytokin levels in beating heart coronary artery bypass graft surgery patients with left ventricular dysfunction. Turkish J of Thorac and Cardiovasc Surg 20:39-43.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).